9,10 Refined pharmacovigilance monitoring as prescription volume continues to climb, allowing researchers to better separate true drug-driven alopecia from weight-loss-driven telogen effluvium
Peptides 151 , 170749 (2022)
The small percentage of patients in the FIDELIO-DKD trial who were on triple combination therapy (receiving an SGLT2i on top of finerenone plus maximum tolerated dose RAAS inhibitor) experienced fewer hyperkalemia events
This comparison breaks down every dimension that matters: receptor pharmacology, published efficacy data, side effect profiles, liver fat effects, dosing protocols, and which compound fits which research question
As those systems adjust, your body may respond in ways that feel new
Indoleamine 2,3-dioxygenase expression in human cancers: Clinical and immunologic perspectives